NASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free IRON Stock Alerts $27.55 +1.03 (+3.88%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$25.64▼$27.9050-Day Range$26.52▼$75.3252-Week Range$25.60▼$77.60Volume368,874 shsAverage Volume420,998 shsMarket Capitalization$665.06 millionP/E RatioN/ADividend YieldN/APrice Target$57.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Disc Medicine alerts: Email Address Disc Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside107.9% Upside$57.29 Price TargetShort InterestBearish14.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$81,408 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.44) to ($5.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector421st out of 913 stocksPharmaceutical Preparations Industry184th out of 420 stocks 4.4 Analyst's Opinion Consensus RatingDisc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDisc Medicine has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.90% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Disc Medicine has recently increased by 2.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRON. Previous Next 3.1 News and Social Media Coverage News SentimentDisc Medicine has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Disc Medicine this week, compared to 3 articles on an average week.Search Interest7 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows9 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $81,408.00 in company stock.Percentage Held by InsidersOnly 4.71% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.44) to ($5.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Disc Medicine Stock (NASDAQ:IRON)Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Read More IRON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRON Stock News HeadlinesApril 16, 2024 | insidertrades.comDisc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 2,560 SharesApril 21, 2024 | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Stock Price Down 4.1%April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 17, 2024 | msn.comDisc Medicine (IRON) Price Target Decreased by 29.78% to 58.25April 12, 2024 | msn.comPerformance Coupe Showdown: 2023 BMW M2 vs. 2024 Ford Mustang Dark HorseApril 9, 2024 | msn.comExplore Outdoors: Step into a 5,000-year-old Native American kitchen in RocklinApril 8, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Intuitive Surgical (ISRG) and Disc Medicine (IRON)April 2, 2024 | msn.comTop 3 Health Care Stocks You'll Regret Missing This MonthApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 1, 2024 | markets.businessinsider.comMaintaining Buy Rating: Bitopertin’s Efficacy in EPP Despite AURORA Study’s Placebo ResponseApril 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Erasca (ERAS)April 1, 2024 | msn.comDisc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo ResponseApril 1, 2024 | markets.businessinsider.comDisc Medicine Tanks 55% On Announcement Of Phase 2 AURORA Topline Data Regarding BitopertinApril 1, 2024 | finance.yahoo.comDisc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity StudyApril 1, 2024 | markets.businessinsider.comDisc Medicine Reports Topline Results From Phase 2 AURORA Study Of Bitopertin - Quick FactsApril 1, 2024 | finance.yahoo.comDisc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity StudyApril 1, 2024 | globenewswire.comDisc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)March 25, 2024 | markets.businessinsider.comBuy Rating for Disc Medicine on Promising Bitopertin Trials and Robust Hematology PipelineMarch 23, 2024 | finance.yahoo.comDisc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal PerformanceMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Trials and Market Potential for Disc Medicine’s BitopertinMarch 21, 2024 | markets.businessinsider.comStable Financials and Promising Pipeline Reinforce Buy Rating for Disc MedicineMarch 21, 2024 | finanznachrichten.deDisc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comDisc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 16, 2024 | finance.yahoo.comIRON Sep 2024 60.000 putMarch 16, 2024 | finance.yahoo.comIRON Jun 2024 40.000 putMarch 16, 2024 | finance.yahoo.comIRON Apr 2024 65.000 callMarch 16, 2024 | finance.yahoo.comIRON Apr 2024 40.000 putSee More Headlines Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IRON CUSIPN/A CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees74Year FoundedN/APrice Target and Rating Average Stock Price Target$57.29 High Stock Price Target$85.00 Low Stock Price Target$40.00 Potential Upside/Downside+107.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.37% Return on Assets-22.27% Debt Debt-to-Equity RatioN/A Current Ratio17.06 Quick Ratio17.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.30 per share Price / Book1.93Miscellaneous Outstanding Shares24,140,000Free Float23,003,000Market Cap$665.06 million OptionableNot Optionable Beta0.18 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Donald William Nicholson Ph.D. (Age 65)Executive Chairman Comp: $164kDr. William Jacob Savage M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $687.74kDr. John D. Quisel Esq. (Age 53)J.D., Ph.D., CEO, President & Director Comp: $750.12kDr. Brian MacDonald ChB (Age 64)MB, Ph.D., Founder & Chair of Scientific Advisory Board Comp: $88.54kMs. Jean M. Franchi (Age 58)Chief Financial Officer Mr. Jonathan Yu M.B.A. (Age 43)Chief Opearating Officer Comp: $539.32kDr. Rahul Khara J.D. (Age 42)Pharm.D., General Counsel, Compliance Officer & Secretary Mr. Srikanth Venkatraman Ph.D.Senior VP & Head of ChemistryMs. Hua Yang Ph.D.Senior Vice President of Nonclinical DevelopmentMs. Pamela Stephenson M.P.H. (Age 55)Chief Commercial Officer More ExecutivesKey CompetitorsPharming GroupNASDAQ:PHARSavaraNASDAQ:SVRAAerovate TherapeuticsNASDAQ:AVTEPraxis Precision MedicinesNASDAQ:PRAXCabaletta BioNASDAQ:CABAView All CompetitorsInsiders & InstitutionsSimplicity Wealth LLCBought 4,566 shares on 4/24/2024Ownership: 0.019%William Richard WhiteSold 2,560 sharesTotal: $81,408.00 ($31.80/share)PNC Financial Services Group Inc.Bought 5,990 shares on 3/22/2024Ownership: 0.041%Wellington Management Group LLPBought 122,981 shares on 3/5/2024Ownership: 0.736%Perceptive Advisors LLCBought 127,404 shares on 2/26/2024Ownership: 4.238%View All Insider TransactionsView All Institutional Transactions IRON Stock Analysis - Frequently Asked Questions Should I buy or sell Disc Medicine stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IRON shares. View IRON analyst ratings or view top-rated stocks. What is Disc Medicine's stock price target for 2024? 7 brokers have issued 1-year target prices for Disc Medicine's shares. Their IRON share price targets range from $40.00 to $85.00. On average, they predict the company's stock price to reach $57.29 in the next year. This suggests a possible upside of 107.9% from the stock's current price. View analysts price targets for IRON or view top-rated stocks among Wall Street analysts. How have IRON shares performed in 2024? Disc Medicine's stock was trading at $57.76 on January 1st, 2024. Since then, IRON shares have decreased by 52.3% and is now trading at $27.55. View the best growth stocks for 2024 here. Are investors shorting Disc Medicine? Disc Medicine saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,860,000 shares, an increase of 47.6% from the March 15th total of 1,260,000 shares. Based on an average daily trading volume, of 431,300 shares, the days-to-cover ratio is presently 4.3 days. View Disc Medicine's Short Interest. When is Disc Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our IRON earnings forecast. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) posted its earnings results on Thursday, March, 21st. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.22. Who are Disc Medicine's major shareholders? Disc Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplicity Wealth LLC (0.02%). Insiders that own company stock include Brian Richard Macdonald, Holdings A/S Novo, Joanne Bryce, Kevin Bitterman, Mona Ashiya, Orbimed Advisors Llc, Rahul Khara, Venture Fund X LP Atlas, William Jacob Savage and William Richard White. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRON) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
